-
admin
Posts
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
– EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU –– Studies include both biologic naïve and experienced patients – HAMPTON,...
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to BOLSTER trial BASKING RIDGE, N.J.,...
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc....
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health,...
Teladoc Health Introduces Pediatric, Adolescent and Family Mental Healthcare Through Partnership with Brightline
Seamless access to a comprehensive range of mental healthcare options provides swift, early intervention and treatment for kids and teens, reduces caregiver stress, promotes healthy...
Bank of America Reports Second Quarter 2024 Financial Results
CHARLOTTE, N.C., July 16, 2024 /PRNewswire/ — Bank of America reported its second quarter 2024 financial results today. The news release, supplemental filing and investor...
Metabolon Expands Library to Include 70 Pesticides, Advancing Human Exposome Insights through Metabolomics
MORRISVILLE, N.C., July 16, 2024 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic,...
Biosyngen’s BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal Carcinoma
SINGAPORE, July 16, 2024 /PRNewswire/ — Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for...
JinkoSolar to Form a Joint Venture with RELC and VI in Saudi Arabia for Production of 10 GW of High-efficiency Solar Cells and Solar Modules
SHANGRAO, China, July 16, 2024 /PRNewswire/ — JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) (NYSE: JKS), one of the largest and most innovative solar...
3rd AUTISM EXPO Concludes Successfully with Celebration and Unity
SEOUL, South Korea, July 16, 2024 /PRNewswire/ — The 3rd AUTISM EXPO 2024 concluded on a high note, featuring a wide range of exhibits and...